Effect of Doxepin and Nortriptyline on Irritable Bowel Syndrome
This study has been completed.
Sponsor:
Qom University of Medical Sciences
Collaborator:
Young Researchers Club
Information provided by:
Qom University of Medical Sciences
ClinicalTrials.gov Identifier:
NCT01268709
First received: December 30, 2010
Last updated: NA
Last verified: December 2010
History: No changes posted
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The objective of this randomized triple blind controlled trial is to compare the effects of Doxepin and Nortriptyline on diarrhea predominant irritable bowel syndrome. In this stuy, 75 patients with IBS are randomly assigned to receive Doxepin , Nortriptyline or placebo, a tablet per day, orally, for two months. Abdominal pain, mucus in the stool, incomplete evacuation, and bloating are measured and compared between groups at the baseline and one and two month after the intervention.
| Condition | Intervention | Phase |
|---|---|---|
|
Irritable Bowel Syndrome |
Drug: Doxepin Drug: Nortriptyline Drug: placebo |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Primary Purpose: Treatment |
Resource links provided by NLM:
Drug Information available for:
Nortriptyline
Nortriptyline hydrochloride
Doxepin hydrochloride
Doxepin
U.S. FDA Resources
Further study details as provided by Qom University of Medical Sciences:
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: doxepin | Drug: Doxepin |
| Active Comparator: nortriptyline | Drug: Nortriptyline |
| Placebo Comparator: placebo | Drug: placebo |
Eligibility| Genders Eligible for Study: | Both |
Criteria
Inclusion Criteria:
- Presence of diarrhea predominant irritable bowel syndrome according to ROME criteria
Exclusion Criteria:
- Gastrointestinal bleeding
- More than 5% weight loss in the last 6 months
- Presence of any finding in favor of organic disorders in the lab tests or organic disorder in colonoscopy of high risk patients
Contacts and Locations
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT01268709 History of Changes |
| Other Study ID Numbers: | YRC-1246 |
| Study First Received: | December 30, 2010 |
| Last Updated: | December 30, 2010 |
| Health Authority: | Iran: Ministry of Health and Medical Education |
Additional relevant MeSH terms:
|
Irritable Bowel Syndrome Colonic Diseases, Functional Colonic Diseases Intestinal Diseases Gastrointestinal Diseases Digestive System Diseases Doxepin Nortriptyline Histamine Antagonists Histamine Agents Neurotransmitter Agents |
Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Physiological Effects of Drugs Antidepressive Agents, Tricyclic Antidepressive Agents Psychotropic Drugs Central Nervous System Agents Therapeutic Uses Adrenergic Uptake Inhibitors Adrenergic Agents Neurotransmitter Uptake Inhibitors |
ClinicalTrials.gov processed this record on May 22, 2013